<DOC>
	<DOC>NCT01492218</DOC>
	<brief_summary>This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.</brief_summary>
	<brief_title>Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin, pork; isophane insulin, pork drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diabetes mellitus (type 1 or type 2) Patient not presently using Mixtard® 30 NovoLet®</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>